Top View
- Evolocumab - Drugbank
- Repatha, INN-Evolocumab
- Evolocumab (Repatha) for Cardiovascular Event Prevention – Add on Therapy
- Lipotropics, Other
- CLINICAL REVIEW(S) Clinical Review Ovidiu A
- Introduction Bile Acid Sequestrants
- New Approaches to Lipid Modification
- Pathway for Prescribing PCSK9 Inhibitors; Alirocumab (Praluent, Sanofi) ▼And Evolocumab (Repatha, Amgen) ▼
- Genetics of Dyslipidemia
- REPATHA (Evolocumab)
- Policy Recommendations
- REPATHA (Evolocumab) Injection, for Subcutaneous Use (On-Body Infusor with Prefilled Cartridge) (3) Initial U.S
- Bempedoic Acid 180Mg Film-Coated Tablets (Nilemdo®) Daiichi Sankyo UK Ltd
- PCSK9 Inhibition: the Way Forward in the Treatment of Dyslipidemia Robert M
- Rare Dyslipidaemias, from Phenotype to Genotype to Management: a European Atherosclerosis Society Task Force Consensus Statement
- Repatha, INN-Evolocumab
- Australian Public Assessment Report for Evolocumab (Rch)
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- The Heart-Disease Vaccine
- Decade in Review—Dyslipidaemia: Resurgence of Targets And
- LIPID LOWERING THERAPIES Llorente Serrano M, Sánchez Gundín J, Rueda Naharro A, Martí Gil C, Martínez Valdivieso L, Barreda Hernández D
- Bococizumab for the Treatment of Hypercholesterolaemia Nicola Ferria, Alberto Corsinib,C, Cesare R
- Repatha, INN-Evolocumab
- Bococizumab for the Treatment of Hypercholesterolaemia Nicola Ferria, Alberto Corsinib,C, Cesare R
- Cardiovascular Outcomes Trials with Non-Statin Lipid-Lowering Drugs in Diabetes
- Bile Acid Sequestrants • Niacin • Fibrates • Mipomersen • Lomitapide • LDL Apheresis Evidence for Treating All FH Patients
- Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
- Lowering Serum Lipids Via PCSK9-Targeting Drugs: Current Advances and Future Perspectives
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9
- Lipotropics, Other Therapeutic Class Review (TCR)
- Guidelines for ATC Classification and DDD Assignment 2021
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: the GLAGOV Randomized Clinical Trial
- PHARMACIST's LETTER / PRESCRIBER's LETTER Non-Statin Lipid-Lowering Agents
- Repatha, INN-Evolocumab
- Alirocumab (Praluent®); Evolocumab (Repatha®) EOCCO POLICY
- A Randomized Study of Evolocumab in Patients with Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the BERSON Clinical Trial Alberto J
- Cholesterol Lowering Agents
- Evolocumab (Heterozygous Hypercholesterolaemia and Mixed Dyslipidaemia) – Benefit Assessment According to §35A Social Code Book V1 (New Scientific Findings)
- Effects (Critical Role) of Nitrite and Nitrate Determinants in Saliva And
- Update on PCSK9 Inhibitors and Statin Intolerance
- REPATHA (Evolocumab) Injection, for Subcutaneous Use Administer REPATHA Subcutaneously Into Areas of the Abdomen, Thigh, Or Initial U.S
- Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
- Application of WHO ATC/ DDD Methods in Medicine Utilisation Research: a Hands-On Experience Ilse Truter 2019
- Therapeutic Class Overview Cholesterol Absorption Inhibitors
- PCSK9 Inhibition for Hyperlipidemia: for Whom? When?
- Tenofovir Alafenamide
- Evolocumab and Clinical Outcomes in Patients with CV Disease FOURIER Study Targeting the Cholesterol Pathway
- Repatha) Reference Number: CP.PHAR.123 Effective Date: 10.01.15 Last Review Date: 02.21 Coding Implications Line of Business: HIM, Medicaid Revision Log
- Pharmacologic Treatment of High Cholesterol, 5.01.558
- Bempedoic Acid with Ezetimibe for Treating Primary Hypercholesterolaemia Or Mixed Dyslipidaemia
- Lack of Cross-Reactivity Allergy Following a Switch from Alirocumab
- A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients
- PCSK9 Inhibitors: When Statins Aren't Enough
- PCSK9 Inhibitors Or Ezetimibe As the Second Line Add-On to Statin Therapy
- Clinical Policy: Evolocumab (Repatha)